ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4

被引：2
|
作者：
Heerspink, Hiddo L.
Sattar, Naveed
Pavo, Imre
Haupt, Axel
Duffin, Kevin L.
Yang, Zhengyu
Wiese, Russell
Tuttle, Katherine R.
Cherney, David
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-17-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of tirzepatide versus insulin glargine 100 U/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4
    Heerspink, H. J. L.
    Sattar, N.
    Pavo, I.
    Haupt, A.
    Duffin, K. L.
    Yang, Z.
    Wiese, R. J.
    Tuttle, K. R.
    Cherney, D. Z. I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S316 - S316
  • [2] Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
    Pearson, Ewan
    Del Prato, Stefano
    Pavo, Imre
    Franco, Denise R.
    Yang, Zhengyu
    Wiese, Russell
    Kahn, Steven E.
    DIABETES, 2022, 71
  • [3] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes
    Paola, Lucidi
    Cioli, Patrizia
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2020, 69
  • [4] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with type 2 diabetes and increased cardiovascular risk: SURPASS-4
    Kahn, S. E.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Wiese, R. J.
    Pearson, E. R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S284 - S284
  • [5] Effects of Tirzepatide vs. Insulin Glargine on Kidney Function Evaluated by Cystatin C-Based eGFR: A Post Hoc Analysis From the SURPASS-4 Trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Wilson, Jonathan M.
    Hemmingway, Andrea
    Cherney, David
    Tuttle, Katherine R.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 677 - 677
  • [6] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Tuttle, Katherine R.
    Cherney, David Z. I.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11): : 774 - 785
  • [7] Insulin degludec vs. Insulin glargine 100 U/ml in diabetes: 2-year results
    Siegmund, T.
    Westrup, D.
    DIABETES STOFFWECHSEL UND HERZ, 2017, 26 (01): : 21 - 28
  • [8] Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Wilson, Jonathan M.
    Hemmingway, Andrea
    Cherney, David Z. I.
    Tuttle, Katherine R.
    DIABETES CARE, 2023, 46 (08) : 1501 - 1506
  • [9] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
  • [10] ADA Presidents' Select Abstract: Effect of Insulin Degludec vs. Insulin Glargine U100 on Occurrence of Nocturnal Hypoglycemia Assessed by Nocturnal Plasma Glucose Profiles in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia
    Brosen, Julie M.
    Agesen, Rikke
    Kristensen, Peter L.
    Alibegovic, Amra Ciric
    Andersen, Henrik U.
    Gustenhoff, Peter
    Hedetoft, Christoffer
    Jensen, Tonny
    Juhl, Claus B.
    Lerche, Susanne
    Norgaard, Kirsten
    Parving, Hans-Henrik D.
    Tarnow, Lise
    Thorsteinsson, Birger
    Pedersen-Bjergaard, Ulrik
    DIABETES, 2021, 70
12345